Celesta Capital led the $16 million Series A round that cancer diagnostics startup OneCell Diagnostics raised. Other investors in the round include Eragon, Singularity Ventures, Cedars Sinai, and Tenacity Ventures.
According to a press release from OneCell, the money will be utilized to bring OncoIndx Alfa, a next-generation liquid biopsy test that finds circulating tumor cells, to the US market.
OneCell was founded in 2021 and uses data analytics, AI/ML, next-generation sequencing, and robust bioinformatics to develop multi-omics biomarkers.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,” said Mohan Uttarwar, CEO and co-founder at OneCell Diagnostics.
Rich biomarkers provided by OncoIndx Alfa help with cancer precision diagnosis and treatment, with applications ranging from monitoring treatment response to tracking disease progression and recurrence.
OneCell has partnerships with Tata Memorial Centre and the All India Institute of Medical Science in New Delhi, according to its website. Stanford University and Harvard Medical School are just two of its strategic academic and business partners.
The company has tested its cell biopsy technology on almost 10,000 patients in India so far, and has already launched a number of solutions.
